2022 International Congress Archives - Page 134 of 153

Machine learning algorithms for classification and analysis of pen-on-paper Archimedes spirals

R. Anandapadmanabhan, A. Vishnoi, D. Biswas, A. Srivastava, D. Joshi, A. Mahabal, R. Rajan (New Delhi, India)
Machine Learning and Instrumented Gait Analysis to Classify Subthalamic DBS States in Parkinson’s Disease

J. Watts, A. Khojandi, R. Ramdhani (Knoxville, USA)
Machine learning supervised classification study for Parkinson`s disease progression through graph-based feature selection method

V. Rama Raju, G. Ramaraju, V. Ramaraju (hyderabad, India)
Machine learning-based classification of SCA1, SCA2, and Healthy controls using graph features

A. Indoria, S. Bhardwaj, AS. Sunny, S. Hegde, N. Kamble, J. Saini, R. Yadav, PK. Pal, RD. Bharath (Bengaluru, India)
Magnetic Resonance Image-guided high-intensity focused ultrasound (MRIgFUS) subthalamotomy in Spanish Parkinson’s disease (PD) patients.

M. Campins-Romeu, R. Baviera-Muñoz, C. Morata-Martinez, I. Sastre-Bataller, R. Conde-Sardon, A. Gutierrez-Martin, I. Martinez-Torres (Valencia, Spain)
Malignant catatonia secondary to clozapine withdrawal: A case report

T. Thammongkolchai, P. Termsarasab (Bangkok, Thailand)
Mania induced by STN-DBS is related to the stimulation of the ventromedial subthalamic nucleus in Parkinson’s disease: a prospective study

SP. Prange, ZL. Lin, MN. Nourredine, TD. Danaila, CL. Laurencin, OLB. Lagha-Boukbiza, MA. Anheim, HK. Klinger, NL. Longato, CP. Phillipps, JV. Voirin, GP. Polo, ES. Simon, PM. Mertens, ASR. Rolland, DD. Devos, EM. Metereau, CT. Tranchant, ST. Thobois (Bron, France)
Manifestations of Parkinson’s Disease in different ethnicities in Sumatera Indonesia: A Descriptive Study

S. Marisdina, S. Handayani, Y. Diansari, A. Afriani, R. Odiesta, M. Nur'Aini (Palembang, Indonesia)
Mapping of the International Classification of Functioning, Disability and Health categories in the Pre-Assessment Information Form for People with Parkinson’s Disease.

F. Rogatto, E. Guelfi, G. Pereira, S. Silva (São Paulo, Brazil)
Mapping Side Effects in Deep Brain Stimulation – Different Approaches, Different Problems.

TA. Dembek, H. Jergas, JN. Petry-Schmelzer, C. Baldermann, J. Strelow, A. Nehls, V. Visser-Vandewalle, MT. Barbe (Cologne, Germany)
Marker Progression and Sample Sizes Estimates for Trials in Prodromal Parkinson’s Disease: A Multicenter Study

S. Joza, M. Hu, KY. Jung, D. Kunz, P. Dusek, D. Arnaldi, B. Högl, L. Ferini-Strambi, M. Terzaghi, F. Sixel-Döring, M. Puligheddu, F. Provini, S. Lewis, J. Liu, J. Bušková, A. Nicoletti, Y. Dauvilliers, C. Bassetti, M. Lawton, HJ. Kim, JS. Sunwoo, F. Bes, K. Sonka, P. Mattioli, A. Stefani, A. Ibrahim, G. Fiamingo, B. Mollenhauer, C. Trenkwalder, M. Figorilli, P. Cortelli, L. Baldelli, K. Ehgoetz Martens, Y. Li, E. Cicero, L. Guiraud, C. Schaefer, A. Pelletier, R. Postuma (Montreal, Canada)
May apomorphine be helpful for the axial symptoms of Parkinson’s Disease?

A. Alonso-Canovas, P. Perez Torre, G. Sanchez Diez, A. Patiño Paton, N. Gonzalez, I. Parees Moreno, JC. Martinez Castrillo (Madrid, Spain)
Measuring functional cognition with the Short Weekly Calendar Planning Activity in patients with Parkinson’s disease and non-manifesting LRRK2 and GBA carriers

T. Schejter Margalit, N. Ben Binyamin, A. Thaler, I. Maidan, J. Cederbaum, A. Orr-Urtreger, M. Gana Weisz, O. Goldstein, N. Giladi, A. Mirelman, R. Kizony (Tel Aviv, Israel)
Measuring what matters in Parkinson’s disease – validating real-world digital mobility outcomes for widespread adoption

A. Yarnall, C. Schlenstedt, P. Ginis, H. Hildesheim, A. Mirelman, J. Hausdorff, A. Nieuwboer, H. Gassner, L. Alcock, P. Brown, H. Hunter, I. Neatrour, L. Sutcliffe, J. Winkler, J. Klucken, J. Kudelka, M. Gordon, C. Becker, W. Maetzler, L. Rochester (Newcastle, United Kingdom)
Mechanisms and Consequences of Weight Gain After Deep Brain Stimulation of the Subthalamic Nucleus in Patients with Parkinson’s Disease

J. Steinhardt, L. Lokowandt, D. Rasche, V. Tronnier, T. Münte, S. Meyhöfer, B. Wilms, N. Brüggemann (Lübeck, Germany)
Medication safety in Parkinson’s disease patients: evaluation of recommendations for decision support in the national drug-disease interaction database

JJ. de Jong, CCM. Stuijt, MME. Diesveld, T. van Laar, SD. Borgsteede (Groningen, Netherlands)
Melatonin attenuates the bidirectional Gut-Brain axis mediated inflammation caused by Ambient Particulate Matter (PM2.5) and averts neurodegeneration

SAM. Panda, VGM. Naidu (Guwahati, India)
Merging global cohorts of manifesting and non-manifesting carriers of pathogenic variants in known Parkinson’s disease genes

K. Roopnarain, E. Vollstedt,, L. Lange, S. Padmanabhan, C. Blauwendraat, A. Singleton, K. Katja, C. Klein (Luebeck, Germany)
Meta-analysis between LARGE-PD cohorts reveals new potential susceptibility regions on the chromosome X

T. Peixoto Leal, S. Rao, M. Inca-Martinez, M. Gouveia, J. French-Kwawu, V. Borda, E. Mason, D. Loesch, A. Horimoto, E. Sarihan, M. Cornejo-Olivas, L. Torres, P. Mazzetti, C. Cosentino, E. Sarapura-Castro, A. Rivera-Valdivia, A. Medina, E. Dieguez, V. Raggio, A. Lescano, V. Tumas, V. Borges, H. Ferraz, C. Rieder, A. Schumacher-Schuh, B. Santos-Lobato, C. Velez-Pardo, M. Jimenez-Del-Rio, F. Lopera, S. Moreno, P. Chana-Cuevas, W. Fernandez, G. Arboleda, H. Arboleda, C. Arboleda-Bustos, D. Yearout, C. Zabetian, T. Thornton, T. O'Connor, I. Mata (Cleveland, USA)
Meta-optimization to select stimulation settings for deep brain stimulation in Parkinson’s disease

M. Connolly, F. Isbaine, J. Willie, R. Gross, A. Devergnas, S. Miocinovic (Atlanta, USA)
Metabolic Biomarkers of Parkinson’s Disease in Peripheral Tissue

L. Mischley, E. Shankland, S. Liu, S. Bhayana, D. Marcinek (Seattle, USA)
Metabolic profile in the brain with Fragile X-associated Tremor/Ataxia Syndrome (FXTAS)

M. Salcedo-Arellano, M. Johnson, Y. Hwang, Y. Mclennan, E. Mcbride, P. Juarez, B. Durbin-Johnson, F. Tassone, R. Hagerman, V. Martinez-Cerdeno (Sacramento, USA)
Metagenomic exploration of the gut microbiome in a sibling-controlled pilot study of children with Tourette Syndrome

L. Sycuro, O. Coker, H. Ramay, K. Muirhead, T. Pringsheim, R. Cortez, D. Martino (Calgary, Canada)
Methods of biochemical diagnosis early stage of Parkinson’s disaese in Uzbekistan

B. Kurbanov (Tashkent, Uzbekistan)
mGlu3 receptors in Parkinson’s disease as a candidate target for neuroprotective therapy: evidence from preclinical studies to human genetic.

M. Alborghetti, L. Di Menna, V. Bruno, G. Battaglia, FE. Pontieri, E. Bianchini, M. Simmaco, M. Borro, F. Nicoletti (Rome, Italy)
MIBG uptakes in the major salivary glands among Lewy body disease using a semi-automatic quantitative method

J. Ebina, S. Mizumura, N. Ishii, Y. Kobayashi, M. Shibukawa, J. Nagasawa, M. Yanagihashi, T. Hirayama, K. Kawabe, S. Orimo, O. Kano (Tokyo, Japan)
Microglial activation facilitates alpha synuclein propagation and neurodegeneration in αSyn preformed fibrils (PFF)-injected PD mouse model

YE. Kim, TT. Lai, F. Richter, HI. Ma (Anyang, Republic of Korea)
Milder presentation in two compound heterozygote cases of spastic paraplegias type 5

A. Zolin, S. Lakhani, H. Sarva (New York, USA)
Mimics or multiplicity: two patients with a PSP phenotype and underlying genetic neurodegenerative disorders.

S. Lyons, R. Walsh, T. Lynch, S. O'Dowd (Dublin, Ireland)
Mindfulness based program for newly diagnosed Parkinson’s patients.

A. Shaji, A. Lasker, N. Ko, M. Solanki, P. Kaur, Y. Ocasio, C. Fanning (Bethlehem, USA)
miR-218-5p Regulates Microglia-mediated Neuroinflammation through Type I Interferon Response in Parkinson’s Disease

D. Wang, Q. Qin, J. Li, J. Zhao, Z. Mao, Z. Xue (Wuhan, China)
Mitochondrial and autophagy alteration in a new fatty acid hydroxylase-associated neurodegeneration (FAHN) model

F. Mandik, S. Misera, Y. Kanana, B. Wilken, C. Klein, M. Vos (Luebeck, Germany)
MoCA and MMSE subitems’ sensitivity across the PD-cognitive spectrum

E. Fiorenzato, L. Zurlo, C. Cianci, M. Garon, T. Gandolfi, F. Pistonesi, L. Weis, A. Antonini, R. Biundo (Padua, Italy)
Modulation of the mesencephalic locomotor region activity during gait in parkinson’s disease patients

Y. Mullie, J. Bourilhon, C. Olivier, A. Collomb-Clerc, K. Lehongre, N. Georges, C. Karachi, M. Welter (Paris, France)
Molecular alterations and pathological remodeling of colonic wall in patients with Parkinson’s disease

G. Bellini, G. Palermo, D. Frosini, L. Benvenuti, C. Pellegrini, M. Bellini, N. Bernardini, M. Fornai, R. Ceravolo (Pisa, Italy)
Molecular diagnosis Approch for Huntington’s Disease in Tunisia

H. Nehdi, E. Chebbi, F. Nabli, Z. Saied, S. Ben Sassi, R. Amouri (Tunis, Tunisia)
Monitoring disease course by sensor-based gait analysis: gait symmetry and motor impairment progression in Parkinson’s disease.

F. Marxreiter, V. Koch, M. Regensburger, S. Stallforth, J. Jukic, J. Klucken, J. Winkler, H. Gassner (Erlangen, Germany)
Monitoring local field potentials recorded after implant surgery from deep brain stimulation leads in the subthalamic nucleus using a sheep animal model

M. Case, C. Zarns, S. Stanslaski (Minneapolis, USA)
Monogenic Hub of the Global Parkinson’s Genetics Program (GP2): In search of new PD genes

L. Lange, ZH. Fang, E. Valente, SY. Lim, A. Tan, A. Illarionova, M. Avenali, I. Keller Sarmiento, H. Madoev, K. Roopnarain, C. Galandra, M. Ellis, K. Kumar, P. Heutink, N. Mencacci, K. Lohmann, C. Klein (Lübeck, Germany)
Month 24 results of a virtual longitudinal, observational study of Parkinson’s disease: The AT-HOME PD cohort

M. Zafar, J. Soto, E. Baloga, L. Omberg, E. Macklin, P. Snyder, K. Amodeo, T. Meyers, S. Duquette, C. Stevens, K. Lizzaraga, E. Nnadika, A. Sarkar, C. Tarolli, J. Adams, C. Lungu, J. Gottesman, B. Valdovinos, E. Dorsey, L. Mangravite, T. Simuni, M. Schwarzchild, R. Schneider (Rochester, USA)
Montreal Cognitive Assessment cutoff point for cognitive impairment in Mexican subjects with PD: A neuropsychological approach

AJ. Hernández-Medrano, GI. Cerda-Hernández, P. Bazán-Rodríguez, E. Reséndiz-Henríquez, E. Ichikawa-Escamilla, MA. Ruiz-Mafud, RA. Abundes-Corona, G. Sánchez-Dinorín, E. Lobato-Ildefonso, A. Cervantes-Arriaga, M. Rodríguez-Violante, R. Solís-Vivanco (Mexico City, Mexico)
More than medications: Patient and care partner perspectives on care for Parkinson’s during hospitalization

J. Shurer, N. Browner (New York, USA)
Mortality in Parkinson’s patients following Covid19 infection in the second wave of the pandemic

G. Desai, T. Nanayakkara, G. Pun, A. Chatterjee, N. Butt (Reading, United Kingdom)
Mosaicism for somatic SNCA copy number variants in multiple system atrophy is related to pathological subtype and presence of α-synuclein inclusions

C. Proukakis, M. Garcia-Segura, D. Perez-Rodriguez, Z. Jaunmuktane (London, United Kingdom)
Motor and non-motor features of Parkinson’s disease in a large cohort of Gaucher’s disease patients

E. Monfrini, I. Trezzi, MC. Malaguti, A. Tessitore, A. Barbato, P. Tirelli, F. Spagnolo, MD. Cappellini, E. Cassinerio, I. Motta, F. Carubbi, F. Nascimbeni, L. Borin, A. Di Fonzo (Milano, Italy)
Motor decision-making in Parkinson’s disease

L. Avanzino, B. Berret, E. Pelosin, M. Bove, T. Pozzo, A. Bisio (Genoa, Italy)
MOTOR DISORDERS IN CONGENITAL SPINAL PATHOLOGY IN CHILDREN

F. Doniyorova (Tashkent, Uzbekistan)
Motor Fluctuations development is associated with non-motor symptoms burden progression in Parkinson´s disease patients. A 2-year follow-up study.

D. Santos, T. de Deus, C. Cores, M. Feal Painceiras, E. Suárez Castro, C. Martínez, S. Jesús, M. Aguilar, P. Pastor, L. Planellas, M. Cosgaya, J. García Caldentey, N. Caballol, I. Legarda, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, M. Avila, V. Gómez Mayordomo, V. Nogueira, V. Puente, J. Dotor, C. Borrué, B. Solano, M. álvarez Sauco, L. Vela, S. Escalante, E. Cubo, F. Carrillo, J. Martínez Castrillo, P. Sánchez Alonso, M. Alonso Losada, N. López Ariztegui, I. Gastón, J. Kulisevsky, M. Blázquez, M. Seijo, J. Ruíz Martínez, C. Valero, M. Kurtis, O. de Fábregues, J. González, R. Alonso Redondo, C. Ordás, L. López Díaz, D. Mcafee, P. Martínez Martín, P. Mir, C. Coppadis (A Coruña, Spain)
Motor resonance flexibility to emotion-enriched context in Parkinson’s disease patients with and without freezing of gait.

E. Pelosin, G. Lagravinese, A. Bisio, M. Bove, A. Botta, G. Bonassi, R. Marchese, S. Mezzarobba, P. Ruggeri, L. Avanzino (Genova, Italy)
Motor-Related and Cognition-Related Safety of Pimavanserin in Patients with Parkinson’s Disease Psychosis (PDP)

V. Abler, C. Ballard, A. Berrio, B. Coate, C. Brain, A. Espay (San Diego, USA)
Motor, epileptic, and developmental phenotypes in genetic disorders affecting G-protein coupled receptor signaling and cAMP metabolism

S. Galosi, L. Pollini, M. Novelli, K. Bernardi, M. Di Rocco, S. Martinelli, V. Leuzzi (Rome, Italy)
Movement disorder practice in a rural setting: challenges and opportunities and utility of telemedicine

P. Karau, R. Mbijiwe (Meru, Kenya)
Movement Disorders Associated With Vitamin B12 Deficiency: A Case Series

R. Zouari, L. Hlioui, F. Nabli, MZ. Saeid, C. Jeridi, S. Blel, S. Ben Sassi (tunis, Tunisia)
Movement Disorders in Hereditary Spastic Paraplegia (HSP): A Systematic Review and Individual Participant Data Meta-Analysis

SM. Fereshtehnejad, P. Saleh, L. Oliveira, N. Patel, S. Bhowmick, G. Saranza, L. Kalia (Ottawa, Canada)
Movement disorders in pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis

M. Jamoussi, H. Benrhouma, Z. Miladi, T. Ben Younes, H. Klaa, I. Kraoua, I. Ben Youssef, M. Ben Ahmed (Tunis, Tunisia)
Movement disorders with phosphodiesterase 10A IgG autoimmunity

C. Valencia-Sanchez, A. Mckeon, A. Zekeridou (Scottsdale, USA)
MPTP-induced structural reorganization of neurons in mice Basal Ganglia: Verifying the sequelae of differential toxicity

B. Bhaduri, I. Datta, R. Yadav, D. Srinivas, P. Alladi (Bangalore, India)
MR imaging features of Dentatorubral-pallidoluysian atrophy (DRPLA): a case report

H. Queirós, I. Carneiro, E. Martins, A. Morgadinho, D. Pereira, G. Cordeiro (Coimbra, Portugal)
MRI biomarkers of freezing of gait development in in Parkinson’s disease

E. Sarasso, S. Basaia, C. Cividini, T. Stojkovic, I. Stankovic, N. Piramide, A. Tomic, V. Markovic, E. Stefanova, VS. Kostic, M. Filippi, F. Agosta (Milano, Italy)
MRI to investigate cerebrovascular changes in Parkinson’s disease

D. Nolan, D. Myall, C. Morgan, R. Shoorangiz, L. Livingston, S. Grenfell, T. Pitcher, M. Macaskill, K-L. Horne, C. Le Heron, S. Marsh, J. Dalrymple-Alford, T. Anderson, T. Melzr (Christchurch, New Zealand)
Multi-modal MRI features and their relationship with clinical scales in Parkinson disease and Atypical Parkinsonian Syndromes

H. Martinez-Hernandez, D. Lopez-Mena, B. Candela-Solano, A. Medina-Islas, L. Alvarez, I. Acosta (Mexico City, Mexico)
Multi-modal prognostic biomarkers for Parkinson’s disease progression and severity

AS. Rolland, M. Dutheil, O. Simonin, R. Viard, V. Huin, M. Kyheng, C. Moreau, S. Thobois, A. Eusebio, E. Hainque, I. Benatru, D. Maltete, C. Giordana, M. Tir, C. Hubsch, B. Jarraya, F. Durif, C. Brefel-Courbon, O. Rascol, JC. Corvol, G. Garçon, D. Devos (Lille, France)
Multicentric prospective study of subthalamic deep brain stimulation 1-year impact on speech in Parkinson’s disease

T. Ollivier (Lille, France)
Multidimensional phenotyping of human stem cell-derived midbrain dopaminergic neurons from a SNCA triplication carrier for drug screening applications

J. Wilbertz, V. Gorgogietas, L. Cousin, A. Vuidel, I. Boussaad, R. Krüger, P. Sommer (Strasbourg, France)
Multimodal assessment of nigrostriatal degeneration in de novo Parkinson’s disease

M. López-Aguirre, M. Matarazzo, J. Blesa, A. Sánchez-Ferro, M. Hm Monje, J. Obeso, J. Pineda-Pardo (Móstoles, Spain)
Multimodal mechanistic disease stratification in sporadic Parkinson’s disease

T. Payne, T. Burgess, M. Sassani, S. Roscoe, S. Bradley, A. Anton, E. Reed, I. Wilkinson, H. Mortiboys, T. Jenkins, O. Bandmann (Sheffield, United Kingdom)
Multimodal MRI assessment of the substantia nigra in premotor and motor stages of parkinsonism

J. Pasquini, MJ. Firbank, L. Best, V. Foster, V. Silani, G. Petrides, DJ. Brooks, KN. Anderson, N. Pavese (Newcastle upon Tyne, United Kingdom)
Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: TALISMAN study rationale and protocol

J. Janssen Daalen, M. Meinders, B. Stunnenberg, H. Groenewoud, P. Ainslie, D. Thijssen, B. Bloem (Nijmegen, Netherlands)
Multiple system atrophy mimicked by mitochondrial disease.

L. Diaz-Feliz, P. Garcia-Ruiz (Madrid, Spain)
Muscarinic M2 cholinergic receptors in cervical dystonia

P. Kassavetis, M. Hosseini, K. Mente, R. Waugh, E. Shamim, W. Dieckmann, P. Herscovitch, M. Hallett, S. Horovitz (Salt Lake City, USA)
Mutant WDR45 leads to altered ferroptosis in β-propeller protein-associated neurodegeneration

S H. Diaw, C. Ganos, S. Zittel, K. Plötze-Martin, L. Kulikovskaja, A. Westenberger, M. Vos, A. Rakovic, M. Dulovic-Mahlow, K. Lohmann (Lübeck, Germany)
Mutation in TUBB4a causing from dystonia to spastic quadriparesis across one family

A. Milovanović, O. Stojiljkovic Tamaš, N. Dragašević Mišković, M. Janković, I. Novaković, M. Svetel, V. Kostić (Belgrade, Serbia)
Mutation screening and burden analysis of AOPEP in dystonia in a Chinese population

J. Lin, C. Li, H. Shang (Chengdu, China)
Mutation screening and burden analysis of MED27 in dystonia in a Chinese population

J. Lin, C. Li, H. Shang (Chengdu, China)
Mutational effects of LRRK2 I1371V in astrocytes derived from patient specific iPSCs

R. Banerjee, I. Datta, S. Jagtap, A. Raj (Bangalore, India)
Myelination relevant plasma microRNA biomarkers identified via an innovative data analytic scheme for differential diagnosis of MSA, an Oligodendroglial Synucleinopathy

CC. Lu, MC. Kuo, JW. Huang, Y-T. Tsai, H-H. Lin Wang, PJ. Kung, C-C. Wu, Y-Y. Hsueh, T. Ochiya, FKH. Phoa, S-P. Lin, R-M. Wu (Taipei, Taiwan)
Myoclonus – encephalopathy induced by ifosfamide in a Non-Hodgkin lymphoma patient

D. Rebolledo García (Mexico City, Mexico)
Myoclonus in a Large Urban Center: 10 Year Experience

K. Oh, M. Hamed, H. Sarva, D. Victor (New York, USA)